肝细胞癌的免疫治疗研究进展

唐雨豪; 王骏成; 朱应钦; 陈锦滨; 张耀军; 周仲国; 陈敏山; 徐立

doi:10.3969/j.issn.1000-8179.2019.09.141

肝细胞癌的免疫治疗研究进展

doi: 10.3969/j.issn.1000-8179.2019.09.141

中山大学肿瘤防治中心肝胆胰科，华南肿瘤学国家重点实验室，肿瘤医学协同创新中心（广州市510060）

基金项目:

国家自然科学基金项目 81772589

国家科技重大专项项目 2018ZX10302205

国家科技重大专项项目 2018ZX10723204

详细信息

作者简介:
唐雨豪专业方向为肝癌的综合治疗和非编码RNA的研究。E-mail：tangyh@sysucc.org.cn

徐立教授，硕士研究生导师，现任中山大学肿瘤防治中心肝胆胰科主任医师。兼任中国抗癌协会肝癌专业委员会青年委员会副主任委员，中华医学会肝病学分会肝癌学组委员，国际肝胆胰协会中国分会肝胆胰MDT专业委员会委员，广东省医学会肝癌分会委员兼秘书等学术职务。主要研究方向为肝癌的综合治疗、腹腔镜肝切除和机器人等微创外科与快速康复技术，在肝癌靶向药物治疗及临床应用方面积累了丰富经验。主持国家自然科学基金面上项目及广东省科技计划项目，参与及主持20余项国际及全国多中心肝癌新药临床研究，发表SCI论文60余篇，以第一或通讯作者身份在Journal of Hepatology（IF 15.040）、Hepatology（IF 14.079）等专业期刊发表论文10余篇，主编专著《小肝癌的多学科治疗》，参与《肝细胞癌合并门静脉癌栓多学科诊治中国共识》等多部肝癌诊疗专家共识的编写。先后荣获2016年度广东省科学技术奖一等奖（第2完成人）及2017年度教育部科学技术进步奖二等奖（第6名），2018年当选为广东省杰出青年医学人才（第一批）

通讯作者:
徐立 xuli@sysucc.org.cn

计量
- 文章访问数: 72
- HTML全文浏览量: 12
- PDF下载量: 16
- 被引次数: 0
出版历程
- 收稿日期: 2019-01-31
- 修回日期: 2019-04-19
- 刊出日期: 2019-05-15

The progress of immunotherapy for hepatocellular carcinoma

Ddepartment of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China

Funds:

the National Natural Science Foundation of China 81772589

National Science and Technology Major Project 2018ZX10302205

National Science and Technology Major Project 2018ZX10723204

More Information

Corresponding author: Li Xu; E-mail:xuli@sysucc.org.cn

摘要

摘要: 肝细胞肝癌（hepatocellular carcinoma，HCC）约占原发肝癌的75%~85%，是全球发病率较高的恶性肿瘤之一，免疫治疗目前被认为是较有前景的防治肝癌术后复发及病情进展的治疗手段。肝癌免疫治疗方案主要分为主动和被动免疫治疗，包括肿瘤疫苗、免疫检查点抑制剂和过继性免疫细胞输注治疗等。本文就近年肝癌免疫治疗的现状和研究进展进行概述。
- 肝细胞癌 /
- 免疫治疗 /
- 免疫检查点抑制剂 /
- 嵌合抗原受体T细胞
Abstract: Hepatocellular carcinoma (HCC) accounts for approximately 75%-85% of primary liver cancer cases and is one of the most frequently diagnosed malignancies worldwide. Immunotherapy is currently considered to be the most promising treatment to prevent the progression and postoperative recurrence of HCC. At present, the treatment strategies of immunotherapy for HCC are classified as active immunotherapy and passive immunotherapy, including tumor vaccine therapy, immune checkpoint inhibitors, and adoptive cell therapy. Here we review the current clinical progression and discuss the future perspective on immune therapy for HCC.
- hepatocellular carcinoma (HCC) /
- immunotherapy /
- immune checkpoint inhibitors /
- chimeric antigen receptor T cell

HTML全文

参考文献(49)

[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. doi: 10.3322/caac.v68.6
[2]	Chedid MF, Kruel CRP, Pinto MA, et al. Hepatocellular carcinoma: diagnosis and operative management[J]. Arq Bras Cir Dig, 2017, 30 (4):272-278. doi: 10.1590/0102-6720201700040011
[3]	Sprinzl MF, Galle PR. Current progress in immunotherapy of hepatocellular carcinoma[J]. J Hepatol, 2016, 66(3):482-484. http://d.old.wanfangdata.com.cn/Periodical/yxxxzz201903015
[4]	Schrader J. The role of MDSCs in hepatocellular carcinoma--in vivo veritas[J]? J Hepatol, 2013, 59(5):921-923. doi: 10.1016/j.jhep.2013.08.003
[5]	El Ansary M, Mogawer S, Elhamid S A, et al. Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC[J]. J Cancer Res Clin Oncol, 2013, 139(1):39-48. doi: 10.1007/s00432-012-1298-8
[6]	Mizukoshi E, Nakamoto Y, Arai K, et al. Enhancement of tumor-specific T- cell responses by transcatheter arterial embolization with dendritic cell infusion for hepatocellular carcinoma[J]. Int J Cancer, 2010, 126(9):2164-2174. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=5bf88e5591591b1512db3907e60b95c3
[7]	Palmer DH, Midgley RS, Mirza N, et al. A phaseⅡ study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma[J]. Hepatology, 2009, 49(1): 124-132. doi: 10.1002/hep.22626
[8]	Thomson AW, Knolle PA. Antigen- presenting cell function in the tolerogenic liver environment[J]. Nature Rev Immunol, 2010, 10 (11):753-766. doi: 10.1038/nri2858
[9]	Buonaguro L. Developments in cancer vaccines for hepatocellular carcinoma[J]. Cancer Immunol, Immunother, 2016, 65(1):93-99. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=8ab37316c27cc5f45b59836116bc438b
[10]	Butterfield LH, Ribas A, Meng WS, et al. T-cell responses to HLAA0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer[J]. Clin Cancer Res, 2003, 9 (16 Pt 1):5902-5908. http://tetramer.yerkes.emory.edu/facility/publications/14676113
[11]	Nakagawa H, Mizukoshi E, Kobayashi E, et al. Association between highavidity t-cell receptors, induced by α-fetoprotein−derived peptides, and anti-tumor effects in patients with hepatocellular carcinoma[J]. Gastroenterology, 2017, 152(6):1395-1406.e10. doi: 10.1053/j.gastro.2017.02.001
[12]	Nobuoka D, Yoshikawa T, Sawada Y, et al. Peptide vaccines for hepatocellular carcinoma[J]. Hum Vaccin Immunother, 2014, 9(1):210- 212. http://d.old.wanfangdata.com.cn/OAPaper/oai_doaj-articles_be6b9430b05fdd121cd8e4f38d261a47
[13]	Tsuchiya N. Potentiality of immunotherapy against hepatocellular carcinoma[J]. World J Gastroenter, 2015, 21(36):10314. doi: 10.3748/wjg.v21.i36.10314
[14]	Schneider H. Reversal of the TCR stop signal by CTLA-4[J]. Science, 2006, 313(5795):1972-1975. doi: 10.1126/science.1131078
[15]	Sangro B, Gomez-Martin C, de la Mata M, et al. A clinical trial of CTLA- 4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C[J]. J Hepatol, 2013, 59(1):81-88. doi: 10.1016/j.jhep.2013.02.022
[16]	Duffy AG, Ulahannan SV, Makorova-Rusher O, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma[J]. J Hepatol, 2017, 66(3):545-551. doi: 10.1016/j.jhep.2016.10.029
[17]	Hato T, Goyal L, Greten TF, et al. Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions[J]. Hepatology, 2014, 60(5):1776-1782. doi: 10.1002/hep.v60.5
[18]	Nikolova M, Lelievre J, Carriere M, et al. Regulatory T cells differentially modulate the maturation and apoptosis of human CD8⁺T-cell subsets[J]. Blood, 2009, 113(19):4556-4565. doi: 10.1182/blood-2008-04-151407
[19]	Umemoto Y, Okano S, Matsumoto Y, et al. Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy[J]. J Gastroenterol, 2015, 50(1):65-75. doi: 10.1007/s00535-014-0933-3
[20]	Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (Anti-PD-1) in melanoma[J]. New Engl J Med, 2013, 369 (2):134-144. doi: 10.1056/NEJMoa1305133
[21]	Harding JJ. Immune checkpoint blockade in advanced hepatocellular carcinoma: an update and critical review of ongoing clinical trials[J]. Fut Oncol, 2018, 14(22):2293-2302. doi: 10.2217/fon-2018-0008
[22]	El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088):2492-2502. doi: 10.1016/S0140-6736(17)31046-2
[23]	Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE- 224): a non- randomised, open- label phase 2 trial[J]. Lancet Oncol, 2018, 19(7):940-952. doi: 10.1016/S1470-2045(18)30351-6
[24]	Wainberg ZA, Segal NH, Jaeger D, et al. Safety and clinical activity of durvalumab monotherapy in patients with hepatocellular carcinoma (HCC)[J]. J Clin Oncol, 2017, 35(15_suppl):4071-4071. doi: 10.1200/JCO.2017.35.15_suppl.4071
[25]	Chapman PB, D'Angelo SP, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma[J]. New Engl J Med, 2015, 373(13):1270-1271. doi: 10.1056/NEJMc1509660
[26]	Hellmann MD, Rizvi NA, Goldman JW, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study[J]. Lancet Oncol, 2017, 18(1):31-41. doi: 10.1016/S1470-2045(16)30624-6
[27]	Kelley RK, Abou-Alfa GK, Bendel JC, et al. Phase Ⅰ/Ⅱ study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses[J]. J Clin Oncol, 2017, 35(15 suppl):4073.
[28]	Kimura T, Kato Y, Ozawa Y, et al. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model[J]. Cancer Sci, 2018, 109(12):3993-4002. doi: 10.1111/cas.13806
[29]	Kato Y, Tabata K, Kimura T, et al. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8 +T cells through reduction of tumor- associated macrophage and activation of the interferon pathway[J]. PLoS One, 2019, 14(2):e0212513. doi: 10.1371/journal.pone.0212513
[30]	Masafumi Ikeda, Max W. Sung, Masatoshi Kudo, et al. A phase 1b trail of Lenvatinib (LEN) plus Pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC)[J]. J Clin Onclol, 2018, 36(15 suppl):4076. doi: 10.1200/JCO.2018.36.15_suppl.4076
[31]	Stacey Stein, Michael J. Pishvaian, Michael S. Lee, et al. Safety and clinical activity of atezolizumab + bevacizumab in a phase ib study in first- line hepatocellular carcinoma[J]. J Clin Oncol, 2018, 36(15 suppl):4074.
[32]	Rougier P, Mitry E, Barbare J, et al. Hepatocellular carcinoma (HCC): an update[J]. Semin Oncol, 2007, 34(2 Suppl 1):S12-20. http://d.old.wanfangdata.com.cn/Periodical/zhsywk201401026
[33]	Li P, Du Q, Cao Z, et al. Interferon-gamma induces autophagy with growth inhibition and cell death in human hepatocellular carcinoma (HCC) cells through interferon- regulatory factor- 1 (IRF- 1)[J]. Cancer Lett, 2012, 314(2):213-222. doi: 10.1016/j.canlet.2011.09.031
[34]	Herzer K, Hofmann T G, Teufel A, et al. IFN-Induced apoptosis in hepatocellular carcinoma involves promyelocytic leukemia protein and TRAIL independently of p53[J]. Cancer Res, 2009, 69(3):855-862. doi: 10.1158/0008-5472.CAN-08-2831
[35]	Murata M, Nabeshima S, Kikuchi K, et al. A comparison of the antitumor effects of interferon- α and β on human hepatocellular carcinoma cell lines[J]. Cytokine, 2006, 33(3):121-128. doi: 10.1016/j.cyto.2005.08.011
[36]	Sun H, Tang Z, Wang L, et al. Postoperative interferon α treatment postponed recurrence and improved overall survival in patients after curative resection of HBV- related hepatocellular carcinoma: a randomized clinical trial[J]. J Cancer R Clin Oncol, 2006, 132(7):458-465. doi: 10.1007/s00432-006-0091-y
[37]	Kasai K, Ushio A, Kasai Y, et al. Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon α- 2b for advanced hepatocellular carcinoma with portal venous invasion[J]. Cancer, 2012, 118(13):3302-3310. doi: 10.1002/cncr.26648
[38]	Obi S, Yoshida H, Toune R, et al. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion[J]. Cancer, 2006, 106(9):1990-1997. doi: 10.1002/(ISSN)1097-0142
[39]	Ji J, Yu L, Yu Z, et al. Development of a miR-26 companion diagnostic test for adjuvant interferon-alpha therapy in hepatocellular carcinoma[J]. Int J Biol Sci, 2013, 9(3):303-312. doi: 10.7150/ijbs.6214
[40]	Coit DG, Thompson JA, Algazi A, et al. Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2016, 14(4):450-473. doi: 10.6004/jnccn.2016.0051
[41]	Motzer RJ, Jonasch E, Agarwal N. Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2017, 15(6):804-834. doi: 10.6004/jnccn.2017.0100
[42]	Zhang R, Zhang Z, Liu Z, et al. Adoptive cell transfer therapy for hepatocellular carcinoma[J]. Front Med, 2019, 13(1):3-11. http://d.old.wanfangdata.com.cn/Periodical/zggdxxxswx-yx201901002
[43]	Jiang J, Wu C, Lu B Cytokine-induced killer cells promote antitumor immunity[J]. J Transl Med, 2013, 11(1):83. doi: 10.1186/1479-5876-11-83
[44]	Lee J H, Lee J, Lim Y, et al. Adjuvant immunotherapy with autologous cytokine- induced killer cells for hepatocellular carcinoma[J]. Gastroenterol, 2015, 148(7):1383-1391. doi: 10.1053/j.gastro.2015.02.055
[45]	Yu R, Yang B, Chi X, et al. Efficacy of cytokine-induced killer cell infusion as an adjuvant immunotherapy for hepatocellular carcinoma: a systematic review and meta-analysis[J]. Drug Des Devel Ther, 2017, (11): 851-864. http://cn.bing.com/academic/profile?id=ab0a372154724f1e5ba09ac0b8601113&encoded=0&v=paper_preview&mkt=zh-cn
[46]	Hoseini SS, Cheung NV. Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies[J]. Cancer Lett, 2017, (399):44-52. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=464a6ffd0ce2888261c4ecffd1167bcd
[47]	Li W, Guo L, Rathi P, et al. Redirecting T cells to glypican-3 with 4- 1bb zeta chimeric antigen receptors results in Th1 polarization and potent antitumor activity[J]. Hum Gene Ther, 2017, 28(5):437-448. doi: 10.1089/hum.2016.025
[48]	Lin M, Liang S, Wang X, et al. Cryoablation combined with allogenic natural killer cell immunotherapy improves the curative effect in patients with advanced hepatocellular cancer[J]. Oncotarget, 2017, 8(47):81967. http://cn.bing.com/academic/profile?id=ddea19bc649c06fbf3bb199c9b0660fe&encoded=0&v=paper_preview&mkt=zh-cn
[49]	Klingemann H Are natural killer cells superior CAR drivers[J]? OncoImmunol, 2014, 3(4): e28147. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4203506/